Raymond James Financial Inc. Takes $15.99 Million Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Raymond James Financial Inc. bought a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 102,061 shares of the company’s stock, valued at approximately $15,989,000. Raymond James Financial Inc. owned 0.35% of Krystal Biotech as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Arizona State Retirement System raised its holdings in Krystal Biotech by 8.5% in the 4th quarter. Arizona State Retirement System now owns 6,242 shares of the company’s stock valued at $978,000 after acquiring an additional 487 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Krystal Biotech by 1.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 243,170 shares of the company’s stock valued at $38,095,000 after acquiring an additional 2,954 shares during the period. US Bancorp DE raised its holdings in Krystal Biotech by 8.7% in the 4th quarter. US Bancorp DE now owns 1,027 shares of the company’s stock valued at $161,000 after acquiring an additional 82 shares during the period. Illinois Municipal Retirement Fund raised its holdings in Krystal Biotech by 11.9% in the 4th quarter. Illinois Municipal Retirement Fund now owns 14,146 shares of the company’s stock valued at $2,216,000 after acquiring an additional 1,505 shares during the period. Finally, Hussman Strategic Advisors Inc. bought a new position in Krystal Biotech in the 4th quarter valued at about $658,000. 86.29% of the stock is owned by institutional investors.

Analysts Set New Price Targets

KRYS has been the topic of several research analyst reports. Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Krystal Biotech in a research report on Thursday, February 20th. Chardan Capital increased their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th. Citigroup increased their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research report on Thursday, February 20th. Finally, HC Wainwright restated a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research report on Friday, February 28th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Krystal Biotech presently has an average rating of “Buy” and an average price target of $220.00.

Insider Activity at Krystal Biotech

In related news, CAO Kathryn Romano sold 750 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now owns 12,604 shares of the company’s stock, valued at $2,208,472.88. This represents a 5.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the transaction, the insider now directly owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. The trade was a 1.68 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is owned by insiders.

Krystal Biotech Trading Up 0.9 %

NASDAQ KRYS opened at $188.50 on Wednesday. The firm has a market capitalization of $5.43 billion, a price-to-earnings ratio of 63.04 and a beta of 0.87. The firm’s 50 day simple moving average is $164.69 and its 200 day simple moving average is $173.58. Krystal Biotech, Inc. has a 1 year low of $141.72 and a 1 year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.29 by $0.23. The business had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm’s revenue was up 116.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.30 EPS. On average, equities research analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).